Insider Selling: uniQure (NASDAQ:QURE) CEO Sells $2,083,550.00 in Stock

uniQure N.V. (NASDAQ:QURE) CEO Matthew Kapusta sold 41,671 shares of the company’s stock in a transaction that occurred on Thursday, June 18th. The shares were sold at an average price of $50.00, for a total value of $2,083,550.00. Following the completion of the transaction, the chief executive officer directly owned 521,795 shares of the company’s stock, valued at $26,089,750. This trade represents a 7.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

uniQure Stock Performance

Shares of uniQure stock opened at $48.85 on Thursday. The company has a quick ratio of 10.40, a current ratio of 10.40 and a debt-to-equity ratio of 0.33. uniQure N.V. has a 52 week low of $8.73 and a 52 week high of $71.50. The firm’s 50 day moving average is $26.59 and its two-hundred day moving average is $22.65. The firm has a market capitalization of $3.08 billion, a P/E ratio of -14.04 and a beta of 0.98.

uniQure (NASDAQ:QURE) last issued its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, topping the consensus estimate of ($0.88) by $0.03. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The business had revenue of $3.56 million during the quarter, compared to the consensus estimate of $5.21 million. Research analysts forecast that uniQure N.V. will post -3.64 EPS for the current fiscal year.

uniQure News Summary

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: uniQure completed pricing on an upsized offering of 4,945,055 ordinary shares at $45.50 each, expected to raise about $225 million in gross proceeds. The added capital should strengthen the balance sheet and help fund its gene therapy pipeline. Article Title
• Neutral Sentiment: The company said the offering is expected to close around June 25, with underwriters also having a 30-day option to buy additional shares. This keeps financing flexibility high, but the near-term impact depends on completion and investor reception. Article Title
• Negative Sentiment: Investors appear worried about dilution because the company is issuing new shares rather than using debt. That pressure likely contributed to the stock’s weakness despite the capital raise. Article Title
• Negative Sentiment: Recent insider selling by the CEO and several directors may also weigh on sentiment, even though some trades were made under pre-arranged plans. Article Title

Institutional Trading of uniQure

A number of institutional investors have recently modified their holdings of the business. Woodline Partners LP grew its holdings in uniQure by 25.0% during the first quarter. Woodline Partners LP now owns 175,806 shares of the biotechnology company’s stock worth $1,864,000 after acquiring an additional 35,175 shares during the period. Legal & General Group Plc acquired a new stake in uniQure in the second quarter valued at $497,000. Marshall Wace LLP lifted its holdings in uniQure by 276.5% in the second quarter. Marshall Wace LLP now owns 222,979 shares of the biotechnology company’s stock valued at $3,108,000 after acquiring an additional 163,749 shares during the period. California State Teachers Retirement System purchased a new stake in shares of uniQure during the 2nd quarter worth $540,000. Finally, Ameriprise Financial Inc. boosted its position in shares of uniQure by 38.6% during the 2nd quarter. Ameriprise Financial Inc. now owns 761,948 shares of the biotechnology company’s stock worth $10,622,000 after purchasing an additional 212,218 shares in the last quarter. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have issued reports on QURE. Stifel Nicolaus set a $28.00 price objective on shares of uniQure in a research note on Tuesday, May 5th. Leerink Partners lifted their target price on uniQure from $36.00 to $70.00 and gave the stock an “outperform” rating in a research report on Thursday, June 18th. Chardan Capital boosted their target price on uniQure from $31.00 to $37.00 and gave the company a “buy” rating in a report on Thursday, April 30th. HC Wainwright reissued a “buy” rating on shares of uniQure in a research report on Thursday, June 18th. Finally, Cantor Fitzgerald upgraded uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 price target on the stock in a research note on Wednesday, June 17th. Twelve equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, uniQure has an average rating of “Moderate Buy” and a consensus target price of $58.92.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno?associated viral (AAV) vector platform, the company designs single?dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.